Long non‐coding RNA ANRIL interacts with microRNA‐34a and microRNA‐125a, and they all correlate with disease risk and severity of Parkinson's disease

• Published in: Journal of clinical laboratory analysis Vol. 36; no. 1; pp. e24037 - n/a
• Main Authors: Yang, Peng, Lin, Guiqing, Wang, Minli, Chen, Xuewei, Huang, Jian
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.01.2022; John Wiley and Sons Inc
• Subjects: Antisense RNA; Biomarkers; INK4 protein; LncRNA ANRIL; MicroRNAs; miRNA; miR‐125a; miR‐34a; Movement disorders; Neurodegeneration; Neurodegenerative diseases; Non-coding RNA; Parkinson's disease; Polymerase chain reaction; Ribonucleic acid; risk; RNA; severity; severity; miR-125a; risk; LncRNA ANRIL; miR-34a; parkinson’s disease
• ISSN: 0887-8013; 1098-2825
• DOI: 10.1002/jcla.24037

Background This study aimed to investigate the correlation of long non‐coding RNA antisense non‐coding RNA in the INK4 locus (lncRNA ANRIL) and its target microRNAs (microRNA‐34a (miR‐34a) and microRNA‐125a (miR‐125a)) with disease risk and severity of Parkinson’s disease (PD). Methods Seventy‐eight PD patients and 78 age‐/gender‐matched controls were consecutively enrolled. Their peripheral blood mononuclear cell samples were collected and proposed for the reverse‐transcription quantitative polymerase chain reaction to complete lncRNA ANRIL, miR‐34a, and miR‐125a measurements. Results LncRNA ANRIL was upregulated, while miR‐34a and miR‐125a were downregulated in PD patients compared to controls (all p < 0.001). Further, they all showed certain values for PD risk identification by ROC curve analyses, among which lncRNA ANRIL showed the highest AUC (AUC: 0.879, 95% CI: 0.824‐0.934). Furthermore, lncRNA ANRIL negatively correlated with miR‐34a (p = 0.016) and miR‐125a (p = 0.005) in PD patients, but not in controls. In addition, lncRNA ANRIL was observed to positively associate with UPDRS‐I score (p = 0.029), UPDRS‐III score (p = 0.006), and UPDRS‐IV score (p = 0.033), while negatively correlated with MMSE score (p = 0.003). These associations were less distinct as to miR‐34a and miR‐125a. Conclusion LncRNA ANRIL interacts with miR‐34a and miR‐125a in PD patients, and they all correlate with disease risk and severity of PD. Totally, 78 PD patients and 78 age‐/gender‐ matched controls were consecutively enrolled. Their peripheral blood mononuclear cell samples were collected and proposed for reverse‐transcription quantitative polymerase chain reaction to complete lncRNA ANRIL, miR‐34a and miR‐125a measurements. The results displayed that lncRNA ANRIL was upregulated, while miR‐34a and miR‐125a were downregulated in PD patients compared to controls. Furthermore, lncRNA ANRIL negatively correlated with miR‐34a and miR‐125ain PD patients. In addition, lncRNA ANRIL was observed to positively associate with UPDRS‐I score while negatively correlate with MMSE score. While these associations were less distinct as to miR‐34a and miR‐125a.